Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2017

01-10-2017 | Review

Wellness and the Role of Comorbidities in Multiple Sclerosis

Authors: Brandon P. Moss, Mary R. Rensel, Carrie M. Hersh

Published in: Neurotherapeutics | Issue 4/2017

Login to get access

Abstract

Multiple sclerosis (MS) is a demyelinating and neurodegenerative disorder of the central nervous system, for which disease modifying therapies (DMTs) are the mainstay treatment approach to reduce inflammatory disease activity and slow worsening disability. In addition to conventional pharmacologic therapy, there is growing interest in the use of lifestyle strategies to support wellness and mitigate disease-related complications in MS. This interest stems from a growing appreciation of the role of certain comorbidities and lifestyle factors on disease activity, disability, mortality, and overall quality of life. While the current literature is not conclusive, there is evidence to suggest a potential role for vitamin D supplementation, tobacco smoking cessation, routine exercise, a plant-based, anti-inflammatory diet, and maintenance of emotional well-being as adjunct therapies to DMTs. In addition to DMTs, lifestyle strategies should be emphasized as part of a management plan focused on overall health and well-being.
Appendix
Available only for authorised users
Literature
1.
Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 2016;86:1014-1021.PubMedPubMedCentralCrossRef
2.
Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014;83:1022-1024.PubMedPubMedCentralCrossRef
3.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-952.PubMedCrossRef
4.
Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61-76.PubMedCrossRef
5.
Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Medical Econ 2013;16:639-647.CrossRef
6.
Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001;54:661-674.PubMedCrossRef
7.
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009;72:117-124.PubMedPubMedCentralCrossRef
8.
Marrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand 2012;125:180-186.PubMedCrossRef
9.
Conway DS, Thompson NR, Cohen JA. Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course. Mult Scler 2017; 23: 277-285.PubMedCrossRef
10.
Marrie RA, Elliott L, Marriott J, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology 2015;84:350-358.PubMedPubMedCentralCrossRef
11.
Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand 2011; 124: 135-141.PubMedCrossRef
12.
Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002;162:2269-2276.PubMedCrossRef
13.
Rippe J. Lifestyle Medicine. New York: CRC Press; 2013.
14.
Bell IR, Caspi O, Schwartz GE, et al. Integrative medicine and systemic outcomes research: issues in the emergence of a new model for primary health care. Arch Intern Med 2002;162:133-140.PubMedCrossRef
15.
Snyderman R, Weil AT. Integrative medicine: bringing medicine back to its roots. Arch Intern Med 2002;162:395-397.PubMedCrossRef
16.
17.
18.
De Rosa V, Procaccini C, Cali G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007;26:241-255.PubMedCrossRef
19.
Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4 + CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-1036.PubMedCrossRef
20.
Matarese G, Carrieri PB, La Cava A, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2005;102:5150-5155.PubMedPubMedCentralCrossRef
21.
Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler 2009;15:105-113.PubMedCrossRef
22.
Pilutti LA, McAuley E, Motl RW. Weight status and disability in multiple sclerosis: An examination of bi-directional associations over a 24-month period. Mult Scler Relat Disord 2012;1:139-144.PubMedCrossRef
23.
Elgar FJ, Stewart JM. Validity of self-report screening for overweight and obesity. Evidence from the Canadian Community Health Survey. Can J Public Health 2008;99:423-427.PubMed
24.
Pinhas-Hamiel O, Livne M, Harari G, Achiron A. Prevalence of overweight, obesity and metabolic syndrome components in multiple sclerosis patients with significant disability. Eur J Neurol 2015;22:1275-1279.PubMedCrossRef
25.
Wens I, Dalgas U, Stenager E, Eijnde BO. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis—a systematic review. Mult Scler 2013;19:1556-1564.PubMedCrossRef
26.
Slawta JN, Wilcox AR, McCubbin JA, Nalle DJ, Fox SD, Anderson G. Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis. Arch Phys Med Rehabil 2003;84:1823-1830.PubMedCrossRef
27.
Lalmohamed A, Bazelier MT, Van Staa TP, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 2012;19:1007-1014.PubMedCrossRef
28.
Lambert CP, Lee Archer R, Evans WJ. Body composition in ambulatory women with multiple sclerosis. Arch Phys Med Rehabil 2002;83:1559-1561.PubMedCrossRef
29.
Slawta JN, McCubbin JA, Wilcox AR, Fox SD, Nalle DJ, Anderson G. Coronary heart disease risk between active and inactive women with multiple sclerosis. Med Sci Sports Exerc 2002;34:905-912.PubMedCrossRef
30.
White LJ, McCoy SC, Castellano V, Ferguson MA, Hou W, Dressendorfer RH. Effect of resistance training on risk of coronary artery disease in women with multiple sclerosis. Scand J Clin Lab Invest 2006;66:351-355.PubMedCrossRef
31.
Mojtahedi MC, Snook EM, Motl RW, Evans EM. Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev 2008;45:851-861.PubMedCrossRef
32.
Khurana SR, Bamer AM, Turner AP, et al. The prevalence of overweight and obesity in veterans with multiple sclerosis. Am J Phys Med Rehabil 2009;88:83-91.PubMedCrossRef
33.
Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996;39:432-441.PubMedCrossRef
34.
Sioka C, Fotopoulos A, Georgiou A, et al. Body composition in ambulatory patients with multiple sclerosis. J Clin Densitom 2011;14:465-470.PubMedCrossRef
35.
36.
Kvistad SS, Myhr KM, Holmoy T, et al. Body mass index influence interferon-beta treatment response in multiple sclerosis. J Neuroimmunol 2015;288:92-97.PubMedCrossRef
37.
Tettey P, Simpson S, Jr., Taylor B, et al. Adverse lipid profile is not associated with relapse risk in MS: results from an observational cohort study. J Neurol Sci 2014;340:230-232.PubMedCrossRef
38.
Tettey P, Simpson S, Jr., Taylor B, et al. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler 2014;20:1737-1744.PubMedCrossRef
39.
Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013;13:37.PubMedPubMedCentralCrossRef
40.
Pilutti LA, Motl RW. Body mass index underestimates adiposity in persons with multiple sclerosis. Arch Phys Med Rehabil 2016;97:405-412.PubMedCrossRef
41.
Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 2015;21:318-331.PubMedPubMedCentralCrossRef
42.
Weinstock-Guttman B, Zivadinov R, Horakova D, et al. Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 2013;84:1186-1191.PubMedCrossRef
43.
Kappus N, Weinstock-Guttman B, Hagemeier J, et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016;87:181-187.PubMed
44.
Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041-1047.PubMedPubMedCentralCrossRef
45.
Marrie RA, Cutter G, Tyry T. Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. Mult Scler 2011;17:1464-1471.PubMedCrossRef
46.
Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006;12:594-598.PubMedCrossRef
47.
Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology 1999;52:63-70.PubMedCrossRef
48.
Dagan A, Gringouz I, Kliers I, Segal G. Disability progression in multiple sclerosis is affected by the emergence of comorbid arterial hypertension. J Clin Neurol 2016;12:345-350.PubMedPubMedCentralCrossRef
49.
50.
Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol 2015;262:2033-2041.PubMedPubMedCentralCrossRef
51.
Salter A, Tyry T, Wang G, Fox RJ, Cutter G, Marrie RA. Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. Neurol Clin Pract 2016;6:397-408.PubMedPubMedCentralCrossRef
52.
Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-59.PubMedPubMedCentralCrossRef
53.
Hirst C, Swingler R, Compston DA, Ben-Shlomo Y, Robertson NP. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry 2008;79:1016-1021.PubMedCrossRef
54.
Wang JL, Reimer MA, Metz LM, Patten SB. Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med 2000;30:309-317.PubMedCrossRef
55.
Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci 2002;205:51-58.PubMedCrossRef
56.
Gulick EE. Correlates of quality of life among persons with multiple sclerosis. Nurs Res 1997;46:305-311.PubMedCrossRef
57.
Jonsson A, Dock J, Ravnborg MH. Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. Acta Neurol Scand 1996;93:229-235.PubMedCrossRef
58.
Carta MG, Moro MF, Lorefice L, et al. Multiple sclerosis and bipolar disorders: the burden of comorbidity and its consequences on quality of life. J Affect Disord 2014;167:192-197.PubMedCrossRef
59.
Butler E, Matcham F, Chalder T. A systematic review of anxiety amongst people with Multiple Sclerosis. Mult Scler Relat Disord 2016;10:145-168.PubMedCrossRef
60.
Minden SL, Ding L, Cleary PD, et al. Improving the quality of mental health care in multiple sclerosis. J Neurol Sci 2013;335:42-47.PubMedCrossRef
61.
Garcia J, Finlayson M. Mental health and mental health service use among people aged 45+ with multiple sclerosis. Can J Commun Ment Health 2005;24:9-22.PubMedCrossRef
62.
Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res 2012;73:411-417.PubMedCrossRef
63.
Kalson-Ray S, Edan G, Leray E, Group SS. An excessive risk of suicide may no longer be a reality for multiple sclerosis patients. Mult Scler 2017; 23: 864-871.PubMedCrossRef
64.
65.
Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler 2015;21:305-317.PubMedPubMedCentralCrossRef
66.
Marrie RA, Fisk JD, Yu BN, et al. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol 2013;13:16.PubMedPubMedCentralCrossRef
67.
Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685-691.PubMedCrossRef
68.
Gilchrist AC, Creed FH. Depression, cognitive impairment and social stress in multiple sclerosis. J Psychosom Res 1994;38:193-201.PubMedCrossRef
69.
Arnett PA, Higginson CI, Voss WD, et al. Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology 1999;13:434-446.PubMedCrossRef
70.
Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-533.PubMedCrossRef
71.
Burns MN, Nawacki E, Siddique J, Pelletier D, Mohr DC. Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med 2013;75:76-82.PubMedCrossRef
72.
Mohr DC, Goodkin DE, Bacchetti P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2000;55:55-61.PubMedCrossRef
73.
Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem 2003;88:695-705.PubMedCrossRef
74.
DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80:1689S-1696S.PubMed
75.
Sutton AL, MacDonald PN. Vitamin D: more than a “bone-a-fide” hormone. Mol Endocrinol 2003;17:777-791.PubMedCrossRef
76.
Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 1983;57:1308-1310.PubMedCrossRef
77.
Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221:1181-1183.PubMedCrossRef
78.
Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-1773.PubMedCrossRef
79.
Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374:334-338.PubMedCrossRef
80.
Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 1987;79:1659-1664.PubMedPubMedCentralCrossRef
81.
Rigby WF, Noelle RJ, Krause K, Fanger MW. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J Immunol 1985;135:2279-2286.PubMed
82.
Tsoukas CD, Provvedini DM, Manolagas SC. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 1984;224:1438-1440.PubMedCrossRef
83.
Bruce D, Yu S, Ooi JH, Cantorna MT. Converging pathways lead to overproduction of IL-17 in the absence of vitamin D signaling. Int Immunol 2011;23:519-528.PubMedPubMedCentralCrossRef
84.
Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem 2010;285:38751-38755.PubMedPubMedCentralCrossRef
85.
Colin EM, Asmawidjaja PS, van Hamburg JP, et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 2010;62:132-142.PubMedCrossRef
86.
Tang J, Zhou R, Luger D, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 2009;182:4624-4632.PubMedPubMedCentralCrossRef
87.
Adorini L, Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum Immunol 2009;70:345-352.PubMedCrossRef
88.
Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009;132:1146-1160.PubMedCrossRef
89.
Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005;11:266-271.PubMedCrossRef
90.
Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220-1224.PubMedCrossRef
91.
van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007;254:581-590.PubMedCrossRef
92.
Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-240.PubMedPubMedCentralCrossRef
93.
Fitzgerald KC, Munger KL, Kochert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol 2015;72:1458-1465.PubMedCrossRef
94.
95.
96.
Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012;18:1144-1151.PubMedCrossRef
97.
Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565-571.PubMedCrossRef
98.
Sotirchos ES, Bhargava P, Eckstein C, et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology 2016;86:382-390.PubMedPubMedCentralCrossRef
99.
Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011;77:1611-1618.PubMedCrossRef
100.
Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1294-1296.PubMedPubMedCentralCrossRef
101.
Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011;311:44-49.PubMedCrossRef
102.
Dorr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012;13:15.PubMedPubMedCentralCrossRef
103.
Bhargava P, Cassard S, Steele SU, et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 2014;39:288-293.PubMedCrossRef
104.
Talhout R, Schulz T, Florek E, van Benthem J, Wester P, Opperhuizen A. Hazardous compounds in tobacco smoke. Int J Environ Res Public Health 2011;8:613-628.PubMedPubMedCentralCrossRef
105.
106.
Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 2003;43:309-334.PubMedCrossRef
107.
Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008;453:106-109.PubMedCrossRef
108.
Duarte JH, Di Meglio P, Hirota K, Ahlfors H, Stockinger B. Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PLOS ONE 2013;8:e79819.PubMedPubMedCentralCrossRef
109.
D'Hooghe M B, Haentjens P, Nagels G, De Keyser J. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol 2012;19:616-624.PubMedCrossRef
110.
Di Pauli F, Reindl M, Ehling R, et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008;14:1026-1030.PubMedCrossRef
111.
112.
Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005;128:1461-1465.PubMedCrossRef
113.
Koch M, van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and progression in multiple sclerosis. Neurology 2007;69:1515-1520.PubMedCrossRef
114.
Manouchehrinia A, Tench CR, Maxted J, Bibani RH, Britton J, Constantinescu CS. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 2013;136:2298-2304.PubMedPubMedCentralCrossRef
115.
Roudbari SA, Ansar MM, Yousefzad A. Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: a study in IRAN, Guilan. J Neurol Sci 2013;330:52-55.PubMedCrossRef
116.
Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV. Smoking and multiple sclerosis: an updated meta-analysis. PLOS ONE 2011;6:e16149.PubMedPubMedCentralCrossRef
117.
Ramanujam R, Hedstrom AK, Manouchehrinia A, et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 2015;72:1117-1123.PubMedCrossRef
118.
O'Gorman CM, Broadley SA. Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia. J Neurol Sci 2016;370:219-223.PubMedCrossRef
119.
Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-850.PubMedCrossRef
120.
Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA. Mortality of patients with multiple sclerosis: a cohort study in UK primary care. J Neurol 2014;261:1508-1517.PubMedPubMedCentralCrossRef
121.
Manouchehrinia A, Weston M, Tench CR, Britton J, Constantinescu CS. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. J Neurol Neurosurg Psychiatry 2014;85:1091-1095.PubMedPubMedCentralCrossRef
122.
123.
Turner AP, Hartoonian N, Maynard C, Leipertz SL, Haselkorn JK. Smoking and physical activity: examining health behaviors and 15-year mortality among individuals with multiple sclerosis. Arch Phys Med Rehabil 2015;96:402-409.PubMedCrossRef
124.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-1930.PubMedCrossRef
125.
Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 2010;21:1151-1154.PubMedCrossRef
126.
American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. J Am Geriatr Soc 2014;62:147-152.CrossRef
127.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-676.PubMedCrossRef
128.
Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002;13:257-264.PubMedCrossRef
129.
Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469.PubMedPubMedCentralCrossRef
130.
Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010;303:1815-1822.PubMedCrossRef
131.
Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-58.PubMedCrossRef
132.
133.
Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006;84:694-697.PubMed
134.
135.
Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001;73:288-294.PubMed
136.
Smolders J, Peelen E, Thewissen M, et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLOS ONE 2010;5:e15235.PubMedPubMedCentralCrossRef
137.
Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2016;3:CD008286.PubMed
138.
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013:CD009329.
139.
Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health 2015;15:689.PubMedPubMedCentralCrossRef
140.
Stamler J. Toward a modern Mediterranean diet for the 21st century. Nutr Metab Cardiovasc Dis 2013;23:1159-1162.PubMedCrossRef
141.
McGuire S. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Washington, DC: US Departments of Agriculture and Health and Human Services, 2015. Adv Nutr 2016;7:202-204.PubMedPubMedCentralCrossRef
142.
Masullo L, Papas MA, Cotugna N, Baker S, Mahoney L, Trabulsi J. Complementary and alternative medicine use and nutrient intake among individuals with multiple sclerosis in the United States. J Community Health 2015;40:153-160.PubMedCrossRef
143.
Wahls TL, Adamson E. The Wahls protocol cooking for life : the revolutionary modern Paleo plan to treat all chronic autoimmune conditions. New York: Avery; 2017.
144.
145.
Varady KA, Hellerstein MK. Alternate-day fasting and chronic disease prevention: a review of human and animal trials. Am J Clin Nutr 2007;86:7-13.PubMed
146.
Yadav V, Marracci G, Kim E, et al. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial. Mult Scler Relat Disord 2016;9:80-90.PubMedCrossRef
147.
Farez MF, Fiol MP, Gaitan MI, Quintana FJ, Correale J. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015;86:26-31.PubMedCrossRef
148.
Saadatnia M, Etemadifar M, Fatehi F, et al. Short-term effects of prolonged fasting on multiple sclerosis. Eur Neurol 2009;61:230-232.PubMedCrossRef
149.
Bisht B, Darling WG, Grossmann RE, et al. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complement Med 2014;20:347-355.PubMedPubMedCentralCrossRef
150.
151.
Motl RW, Sandroff BM. Benefits of exercise training in multiple sclerosis. Curr Neurol Neurosci Rep 2015;15:62.PubMedCrossRef
152.
Pilutti LA, Platta ME, Motl RW, Latimer-Cheung AE. The safety of exercise training in multiple sclerosis: a systematic review. J Neurol Sci 2014;343:3-7.PubMedCrossRef
153.
Pearson M, Dieberg G, Smart N. Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil 2015;96:1339-1348.PubMedCrossRef
154.
Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142-148.PubMedCrossRef
155.
Gunn H, Markevics S, Haas B, Marsden J, Freeman J. Systematic review: the effectiveness of interventions to reduce falls and improve balance in adults with multiple sclerosis. Arch Phys Med Rehabil 2015;96:1898-1912.PubMedCrossRef
156.
Heine M, van de Port I, Rietberg MB, van Wegen EE, Kwakkel G. Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2015:CD009956.
157.
Sandroff BM, Motl RW, Scudder MR, DeLuca J. Systematic, Evidence-based review of exercise, physical activity, and physical fitness effects on cognition in persons with multiple sclerosis. Neuropsychol Rev 2016;26:271-294.PubMedCrossRef
158.
Sandroff BM, Johnson CL, Motl RW. Exercise training effects on memory and hippocampal viscoelasticity in multiple sclerosis: a novel application of magnetic resonance elastography. Neuroradiology 2017;59:61-67.PubMedCrossRef
159.
Amatya B, Khan F, La Mantia L, Demetrios M, Wade DT. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev 2013:CD009974.
160.
161.
Multiple Sclerosis: NCHPAD - Building Inclusive Communities. www.nchpad.org/70/527/Multiple~Sclerosis. Accessed On: 8/4/17
162.
Fiest KM, Walker JR, Bernstein CN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord 2016;5:12-26.PubMedCrossRef
163.
Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry 2008;30:40-48.PubMedCrossRef
164.
Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69:942-949.PubMedCrossRef
165.
Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990;147:1493-1497.PubMedCrossRef
166.
Solaro C, Bergamaschi R, Rezzani C, et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol 2013;36:114-116.PubMedCrossRef
167.
Shafey H. The effect of fluoxetine in depression associated with multiple sclerosis. Can J Psychiatry 1992;37:147-148.PubMedCrossRef
168.
Scott TF, Nussbaum P, McConnell H, Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995;17:421-422.PubMed
169.
Dean G. A double-blind trial with an antidepressant drug, imipramine, in multiple sclerosis. S Afr Med J 1969;43:86-87.PubMed
170.
Paparrigopoulos T, Ferentinos P, Kouzoupis A, Koutsis G, Papadimitriou GN. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry 2010;22:14-21.PubMedCrossRef
171.
172.
Simpson R, Booth J, Lawrence M, Byrne S, Mair F, Mercer S. Mindfulness based interventions in multiple sclerosis--a systematic review. BMC Neurol 2014;14:15.PubMedPubMedCentralCrossRef
173.
Mills N, Allen J. Mindfulness of movement as a coping strategy in multiple sclerosis. A pilot study. Gen Hosp Psychiatry 2000;22:425-431.PubMedCrossRef
174.
Tavee J, Rensel M, Planchon SM, Butler RS, Stone L. Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study. Int J MS Care 2011;13:163-168.PubMedPubMedCentralCrossRef
175.
Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 2010;75:1141-1149.PubMedPubMedCentralCrossRef
Metadata
Title
Wellness and the Role of Comorbidities in Multiple Sclerosis
Authors
Brandon P. Moss
Mary R. Rensel
Carrie M. Hersh
Publication date
01-10-2017
Publisher
Springer US
Published in
Neurotherapeutics / Issue 4/2017
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-017-0563-6

Other articles of this Issue 4/2017

Neurotherapeutics 4/2017 Go to the issue

Editorial

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead

Review

Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis

Original Article

Effectiveness of Daily Prednisolone to Slow Progression of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Multicenter Retrospective Cohort Study

Original Article

Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington’s Disease Mice

Review

Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials

Review

Remyelinating Pharmacotherapies in Multiple Sclerosis